Clinical Trial

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-08-10; most recent amendment 2026-01-26.
Status change: Recruiting → Active, Not Recruiting 2026-01-26
Status change: Not Yet Recruiting → Recruiting 2022-12-27
Trial Details
NCT Number NCT05500092
Lead Sponsor Montefiore Medical Center
Collaborators: Bristol-Myers Squibb, Penn State University, Washington University School of Medicine
Conditions Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Enrollment 17 participants
Start Date 2023-01-25
Primary Completion 2025-07-01 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-28